Status:

TERMINATED

Hydralazine and Valproate Added to Chemotherapy for Breast Cancer

Lead Sponsor:

National Institute of Cancerología

Collaborating Sponsors:

National Council of Science and Technology, Mexico

Psicofarma, S.A. De C.V.

Conditions:

Locally Advanced Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

Aberrant DNA methylation and histone deacetylation participate in cancer development and progression, as epigenetic alterations are common to breast cancer, in this phase II study, the demethylating h...

Detailed Description

Eligible patients after signing the informed consent and will undergo study evaluation and then typed for acetylator phenotype before being treated with hydralazine at 182 mg for rapid-, or 83 mg for ...

Eligibility Criteria

Inclusion

  • Aged 18 and older; histologically proven invasive T2-3, N0-2, and M0 (stages IIB-IIIA) breast carcinoma; Eastern Cooperative Oncology Group performance status ≤2. Hematological function: Absolute leukocyte count ≥4,000/mm3, platelets ≥100,000/mm3, hemoglobin ≥9.0 g/dL. Hepatic function: total bilirubin, aspartate amino transferase and alanine amino transferase \<1.5 the upper normal limit. Renal function: creatinine ≤1.2 mg/dL or a calculated creatinine clearance of ≥60 mL/min. Written informed consent.

Exclusion

  • A history of allergy to sulphas, hydralazine, or magnesium valproate. Past or present condition of rheumatic disease, central nervous system disease, heart failure from aortic stenosis and postural hypotension as diagnosed by a physician. Previous use of the experimental drugs. Pregnancy and breast-feeding. Uncontrolled systemic disease or infection.

Key Trial Info

Start Date :

June 1 2005

Trial Type :

INTERVENTIONAL

End Date :

August 1 2006

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT00395655

Start Date

June 1 2005

End Date

August 1 2006

Last Update

November 3 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Instituto Nacional de Cancerologia

Mexico City, TLALPAN, Mexico, 14080